

July 26, 2025

To
The Corporate Relations Department,
BSE Limited,
Company Code No. **526301**

Dear Sir/Madam,

Subject: Outcome of the Board Meeting held on July 26, 2025.

We hereby inform you that, the Board of Directors in their meeting held today i.e. on **Saturday, July 26, 2025**, has inter-alia considered and approved the Un-audited Standalone and Consolidated Financial Results of the Company for the First Quarter ended June 30, 2025.

A signed copy of the above Financial Results along with Limited Review Report issued by the Statutory Auditors thereon under Regulation 33 of the Listing Regulations are enclosed to this letter.

The Meeting commenced at 11:00 A.M. (IST) and concluded at 12:00 Noon. (IST).

Kindly take the same on record.

Thanking You.

For **Medinova Diagnostic Services Limited**

HANSRAJ SINGH
Digitally signed by
HANSRAJ SINGH
Date: 2025.07.26
12:10:26 +05'30'

Hansraj Singh
Company Secretary & Compliance Officer
M. No. F11438

M. ANANDAM & CO.,
CHARTERED ACCOUNTANTS

**Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of
the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015**

**Review Report to the Board of Directors
Medinova Diagnostic Services Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Medinova Diagnostic Services Limited (the "Company") for the quarter ended 30th June, 2025 and year to date results for the period 1st April, 2025 to 30th June, 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "LODR Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Emphasis of Matter

The Company has obtained approval of its shareholders on April 25, 2025 for the Scheme of Amalgamation of the Company with and into the Holding Company, "Vijaya Diagnostic Centre Limited" with effect from 01st April, 2024. The Scheme is subject to the approval of the National Company Law Tribunal, Hyderabad.

For M. Anandam & Co.,
Chartered Accountants
(Firm Regn.No.000125S)

ABHIRAM
VENKATA
MAMIDIPUDI

Digitally signed by
ABHIRAM VENKATA
MAMIDIPUDI
Date: 2025.07.26
11:50:38 +05'30'

M. V. Abhiram

Partner

Membership Number: 266427

UDIN: 25266427BMLFPI9102

Place: Secunderabad

Date: 26-07-2025



MEDINOVA DIAGNOSTIC SERVICES LIMITED

CIN: L85110TG1993PLC015481

Regd. Office : H.No. 7-1-58, Unit No. 1/Flat No.301, 3rd Floor, Amrutha Business Complex, Ameerpet, Hyderabad - 500 016.

Statement of Unaudited Standalone Financial Results for the quarter ended 30 June 2025

		(Rs. in Lakhs)		
Sl. No.	Particulars	Quarter Ended		Year Ended
		30 June 2025	31 March 2025	30 June 2024
		Unaudited	Audited (Refer Note 3)	Unaudited
1	Income:			
	(a) Revenue from Operations	207.83	197.02	185.51
	(b) Other Income	2.89	3.15	1.99
	Total Income	210.72	200.17	187.50
2	Expenses			
	(a) Cost of Materials Consumed	11.52	8.52	16.54
	(b) Employee Benefits Expense	38.13	39.47	41.66
	(c) Testing Fees	22.06	26.52	15.02
	(d) Finance Costs	11.85	12.33	12.47
	(e) Depreciation and amortisation expenses	3.45	3.69	3.15
	(f) Other Expenses	75.70	70.57	76.81
	Total Expenses	162.71	161.10	165.65
3	Profit before Tax [1-2]	48.01	39.07	21.85
4	Tax Expense			
	(a) Current Tax	11.10	5.33	2.10
	(b) Earlier Year's Tax	-	0.42	-
	(c) Deferred Tax	1.28	5.52	3.12
	Total tax expense	12.38	11.27	5.22
5	Profit/Loss for the period (3-4)	35.63	27.80	16.63
6	Other Comprehensive Income			
	Items that will not be reclassified to Profit or Loss :			
	i) Remeasurement of defined benefit plans	(0.73)	(2.64)	-
	ii) Income tax relating to above	0.18	0.67	-
7	Total Comprehensive Income for the period (5+6)	35.08	25.82	16.63
8	Paid-up Equity Share capital (Face Value Rs 10/- per share)	995.68	995.68	995.68
9	Earnings per Equity Share (not annualised)			
	a) Basic (Rs.)	0.36	0.28	0.17
	b) Diluted (Rs.)	0.36	0.28	0.17

Notes

- The above Standalone financial results of Medinova Diagnostic Services Limited ("the Company") have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The above standalone financial results were reviewed by the audit committee and approved by the Board of Directors in their respective meetings held on 26 July 2025. The above results are subjected to audit by the statutory auditors of the company. An unmodified report has been issued by them thereon.
- The standalone figures for the quarter ended 31 March 2025 are the balancing figures between the audited standalone figures in respect of the full financial year and the published unaudited year to date standalone figures up to the third quarter of the financial years.
- The Company has one reportable segment (viz. Diagnostic Services) as per the requirements of Ind AS 108 "Operating Segments".
- The Board of Directors of the Company at their meeting held on 26 June 2024, have considered and approved the proposed Scheme of Amalgamation ("Scheme") of the company ("Transferor Company") with and into the Holding Company, "Vijaya Diagnostic Centre Limited" (Transferee Company) with effect from 01 April 2024 ('the Appointed Date') under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013, and other rules and regulations framed thereunder ("Scheme"). The Company has received letter with "no adverse observations" from the BSE Limited and SEBI on December 05, 2024, and further vide National Company Law Tribunal ("NCLT"), Hyderabad, order dated March 5, 2025 ("Order"), the company has obtained approval of shareholders vide resolution passed at their meeting held on April 25, 2025, and pursuant to the said order the NCLT has also dispensed the meeting of Unsecured Creditors and Unsecured Loan Creditor as they have conveyed their consent in writing for the Scheme of Amalgamation. The Scheme is subject to the approval of the NCLT, and such other approvals, permissions, and sanctions of regulatory and other authorities as may be necessary.

Place: Hyderabad
Date: 26 July 2025

For Medinova Diagnostic Services Limited

SUNIL
CHANDRA
KONDAPALLY
Sunil Chandra Kondapally
Managing Director
DIN 01409332

Digitally signed by SUNIL
CHANDRA KONDAPALLY
Date: 2025.07.26 11:24:03
+05'30'

M. ANANDAM & CO.,
CHARTERED ACCOUNTANTS

**Independent Auditor's Review Report on the Quarterly Consolidated Unaudited Financial Results of the
Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015**

**Review Report to the Board of Directors
Medinova Diagnostic Services Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Medinova Diagnostic Services Limited ("the Holding Company") and its subsidiary (the Holding Company and its subsidiary together referred to as "the Group") for the quarter ended 30th June, 2025 and year to date results for the period 1st April, 2025 to 30th June, 2025 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "LODR Regulations").
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. The Statement includes the results of the subsidiary, Medinova Millenium MRI Services LLP.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited consolidated financial results, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Emphasis of Matter

The Holding Company has obtained approval of its shareholders on April 25, 2025 for the Scheme of Amalgamation of the Holding Company with and into the ultimate Holding Company, "Vijaya Diagnostic Centre Limited" with effect from 01st April, 2024. The Scheme is subject to the approval of the National Company Law Tribunal, Hyderabad.

For M. Anandam & Co.,
Chartered Accountants
(Firm Regn.No.000125S)

ABHIRAM
VENKATA
MAMIDIPUDI

Digitally signed by
ABHIRAM VENKATA
MAMIDIPUDI
Date: 2025.07.26
11:51:07 +05'30'

M. V. Abhiram

Partner

Membership Number: 266427

UDIN: 25266427BMLFPJ6858

Place: Secunderabad

Date: 26-07-2025

MEDINOVA DIAGNOSTIC SERVICES LIMITED

CIN: L85110TG1993PLC015481

Regd. Office : H.No. 7-1-58, Unit No. 1/Flat No.301, 3rd Floor, Amrutha Business Complex, Ameerpet, Hyderabad - 500 016.

Statement of Unaudited Consolidated Financial Results for the quarter ended 30 June 2025

(Rs. in Lakhs)

Sl. No.	Particulars	Quarter Ended		Year Ended	
		30 June 2025	31 March 2025	30 June 2024	31 March 2025
		Unaudited	Audited (Refer Note 3)	Unaudited	Audited
1	Income:				
	(a) Revenue from Operations	272.13	251.07	249.05	981.29
	(b) Other Income	5.63	7.45	1.67	14.56
	Total Income	277.76	258.52	250.72	995.85
2	Expenses				
	(a) Cost of Materials Consumed	14.50	11.96	20.54	64.32
	(b) Employee Benefits Expense	42.44	45.28	47.15	182.60
	(c) Testing Fees	22.06	17.56	15.02	74.44
	(d) Finance Costs	11.85	12.33	12.47	50.00
	(e) Depreciation	3.51	3.77	3.26	14.47
	(f) Other Expenses	87.44	91.70	96.83	360.36
	Total Expenses	181.80	182.60	195.27	746.19
3	Profit before Tax	95.96	75.92	55.45	249.66
4	Tax Expense				
	(a) Current Tax	27.63	10.19	9.45	47.55
	(b) Earlier Year's Tax	-	0.42	-	0.42
	(c) Deferred Tax	2.25	5.78	3.76	12.02
	Total tax expense	29.88	16.40	13.21	59.99
5	Profit/Loss for the period (3-4)	66.08	59.52	42.24	189.67
6	Other Comprehensive Income				
	Items that will not be reclassified to Profit or Loss :				
	i) Remeasurement of defined benefit plans	(0.73)	(2.64)	-	(2.64)
	ii) Income tax relating to above	0.18	0.67	-	0.67
7	Total Comprehensive Income for the period (5+6)	65.53	57.54	42.24	187.69
	Net Profit attributable to:				
	(a) Owners of the Company	66.08	59.52	42.24	189.67
	(b) Non Controlling Interest	-	-	-	-
	Other Comprehensive Income attributable to:				
	(a) Owners of the Company	(0.55)	(1.98)	-	(1.98)
	(b) Non Controlling Interest	-	-	-	-
	Total Comprehensive Income attributable to:				
	(a) Owners of the Company	65.53	57.54	42.24	187.69
	(b) Non Controlling Interest	-	-	-	-
8	Paid-up Equity Share capital (Face Value Rs 10/- per share)	995.68	995.68	995.68	995.68
9	Earnings per Equity Share (not annualised)				
	a) Basic (Rs.)	0.66	0.60	0.42	1.89
	b) Diluted (Rs.)	0.66	0.60	0.42	1.89

Notes

1. The above Consolidated financial results of Medinova Diagnostic Services Limited ("the Company") have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements)
2. The above consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 26th July, 2025. The Statutory Auditors of the Company have expressed an unmodified audit opinion on these results
3. The consolidated figures for the quarter ended 30 June 2025 are the balancing figures between the audited consolidated figures in respect of the full financial year and the published unaudited year to date consolidated figures up to the third quarter of the respective financial year.
4. The above results include the results of the wholly owned subsidiary, Medinova Millennium MRI Services LLP.
5. The Group has one reportable segment (viz. Diagnostic Services) as per the requirements of Ind AS 108 "Operating Segments".
6. The Group has prepared consolidated financial results based on Ind AS 110 "Consolidated Financial Statements".
7. The Board of Directors of the Company at their meeting held on 26 June 2024, have considered and approved the proposed Scheme of Amalgamation ("Scheme") of the company ("Transferor Company") with and into the Holding Company, "Vijaya Diagnostic Centre Limited" (Transferee Company) with effect from 01 April 2024 ('the Appointed Date') under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013, and other rules and regulations framed thereunder ("Scheme"). The Company has received letter with "no adverse observations" from the BSE Limited and SEBI on December 05, 2024, and further vide National Company Law Tribunal ("NCLT"), Hyderabad, order dated March 5, 2025 ("Order"), the company has obtained approval of shareholders vide resolution passed at their meeting held on April 25, 2025, and pursuant to the said order the NCLT has also dispensed the meeting of Unsecured Creditors and Unsecured Loan Creditor as they have conveyed their consent in writing for the Scheme of Amalgamation. The Scheme is subject to the approval of the NCLT, and such other approvals, permissions, and sanctions of regulatory and other authorities as may be necessary.

Place: Hyderabad
Date : 26 July 2025

For Medinova Diagnostic Services Limited

SUNIL
CHANDRA
KONDAPALLY

Digitally signed by SUNIL
CHANDRA KONDAPALLY
Date: 2025.07.26 11:22:50
+05'30'

Sunil Chandra Kondapally
Managing Director
DIN 01409332